Patents Assigned to Calydon
-
Patent number: 7011976Abstract: Replication competent adenoviral vectors specific for cells expressing alfa-fetoprotein (AFP) are provided. These replication-competetent adenoviral vectors comprise adenovirus genes essential for replication under the transcriptional control of an AFP-transcriptional regulatory element.Type: GrantFiled: March 3, 1998Date of Patent: March 14, 2006Assignee: Calydon, Inc.Inventors: Andrew S. Little, Henry G. Lamparski, Daniel R. Henderson, Eric R. Schuur
-
Patent number: 6495130Abstract: The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.Type: GrantFiled: December 29, 1999Date of Patent: December 17, 2002Assignee: Calydon, Inc.Inventors: Daniel R. Henderson, De Chao Yu
-
Patent number: 6254862Abstract: Adenovirus vectors replication specific for cells expressing &agr;-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.Type: GrantFiled: March 2, 1998Date of Patent: July 3, 2001Assignee: Calydon, Inc.Inventors: Andrew S. Little, Daniel R. Henderson, Eric R. Schuur, Henry Lamparski
-
Patent number: 6197293Abstract: Replication-competent adenovirus vectors specific for cells which allows a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.Type: GrantFiled: March 2, 1998Date of Patent: March 6, 2001Assignee: Calydon, Inc.Inventors: Daniel R. Henderson, Eric R. Schuur, De-Chao Yu
-
Patent number: 6136792Abstract: The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene constructs.Type: GrantFiled: July 11, 1997Date of Patent: October 24, 2000Assignee: Calydon, Inc.Inventor: Daniel R. Henderson
-
Patent number: 6057299Abstract: The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene constructs.Type: GrantFiled: September 27, 1996Date of Patent: May 2, 2000Assignee: Calydon, Inc.Inventor: Daniel R. Henderson
-
Patent number: 6051417Abstract: Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line containing an expression construct comprising a transciptional initiation region of a prostate specific enhancer from a human glandular kallikrein (hKLK2) gene is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.Type: GrantFiled: August 4, 1997Date of Patent: April 18, 2000Assignee: Calydon, Inc.Inventors: Daniel R. Henderson, Eric R. Schuur, Henry G. Lamparski, De-Chao Yu
-
Patent number: 5871726Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.Type: GrantFiled: June 26, 1996Date of Patent: February 16, 1999Assignee: Calydon, Inc.Inventors: Daniel Robert Henderson, Eric Rodolph Schuur
-
Patent number: 5830686Abstract: The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotides comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene contructs.Type: GrantFiled: January 13, 1994Date of Patent: November 3, 1998Assignee: CalydonInventor: Daniel R. Henderson
-
Patent number: 5698443Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.Type: GrantFiled: June 27, 1995Date of Patent: December 16, 1997Assignee: Calydon, Inc.Inventors: Daniel Robert Henderson, Eric Rodolph Schuur